Drug combination therapy shows promise in cancer treatment by addressing drug resistance, reducing toxicity, and enhancing therapeutic efficacy. However, the intricate and dynamic nature of biological systems makes identifying potential synergistic drugs a costly and time-consuming endeavor. To facilitate the development of combination therapy, techniques employing artificial intelligence have emerged as a transformative solution, providing a sophisticated avenue for advancing existing therapeutic approaches. In this study, we developed SynerGNet, a graph neural network model designed to accurately predict the synergistic effect of drug pairs against cancer cell lines. SynerGNet utilizes cancer-specific featured graphs created by integrating heterogeneous biological features into the human protein–protein interaction network, followed by a reduction process to enhance topological diversity. Leveraging synergy data provided by AZ-DREAM Challenges, the model yields a balanced accuracy of 0.68, significantly outperforming traditional machine learning. Encouragingly, augmenting the training data with carefully constructed synthetic instances improved the balanced accuracy of SynerGNet to 0.73. Finally, the results of an independent validation conducted against DrugCombDB demonstrated that it exhibits a strong performance when applied to unseen data. SynerGNet shows a great potential in detecting drug synergy, positioning itself as a valuable tool that could contribute to the advancement of combination therapy for cancer treatment.

SynerGNet is a novel approach to predicting drug synergy against cancer cell lines. In this study, we discuss in detail the construction process of SynerGNet, emphasizing its comprehensive design tailored to handle complex data patterns. Additionally, we investigate a counterintuitive phenomenon when integrating more augmented data into the training set results in an increase in testing loss alongside improved predictive accuracy. This sheds light on the nuanced dynamics of model learning. Further, we demonstrate the effectiveness of strong regularization techniques in mitigating overfitting, ensuring the robustness and generalization ability of SynerGNet. Finally, the continuous performance enhancements achieved through the integration of augmented data are highlighted. By gradually increasing the amount of augmented data in the training set, we observe substantial improvements in model performance. For instance, compared to models trained exclusively on the original data, the integration of the augmented data can lead to a 5.5% increase in the balanced accuracy and a 7.8% decrease in the false positive rate. Through rigorous benchmarks and analyses, our study contributes valuable insights into the development and optimization of predictive models in biomedical research.

Accurate prediction of enzyme turnover numbers ($k_{cat}$) is essential for applications in systems biology, metabolic engineering, and drug discovery, yet remains challenging due to the limited availability and uneven distribution of experimental data. Here, we present AUKAT, an integrated framework that combines conditional generative modeling with deep neural prediction to improve $k_{cat}$ estimation. A conditional variational autoencoder generates synthetic training instances in embedding space, followed by a selection pipeline that retains samples with strong agreement across independent evaluators, thereby ensuring data reliability. A hybrid convolutional neural network and transformer-based architecture is then used to predict $k_{cat}$ from substrate, enzyme functional, and species embeddings. Incorporating synthetic data improved predictive performance for both random forest and neural network models in five-fold cross-validation, with larger gains observed for the neural network architecture. Benchmarking against DLKcat demonstrated comparable predictive accuracy on the standard test set, while evaluation on stricter unseen subsets indicated improved generalization for low-similarity substrates and enzymes. Feature importance analysis further showed that AUKAT leverages substrate, enzyme functional, and species information in a more balanced manner rather than relying predominantly on a single feature source. In addition, AUKAT-human, a specialized model trained using a pre-training and fine-tuning strategy, achieved improved prediction accuracy for human enzyme kinetics. Overall, AUKAT provides a scalable approach for enzyme kinetics prediction and offers a practical solution to data scarcity in biochemical modeling.